Heart failure reflects impaired cardiac contractility and/or relaxation, resulting from myocardial infarction, hypertension, cardiomyopathy, or valvular disease.
Heart failure reflects impaired cardiac contractility and/or relaxation, resulting from myocardial infarction, hypertension, cardiomyopathy, or valvular disease. Progressive cardiomyocyte death, fibrotic remodelling, and neuroendocrine dysregulation drive the syndrome. Placental mesenchymal stem cells and their exosomes limit adverse remodelling by secreting anti-fibrotic factors (anti-TGF-β signalling), promoting angiogenesis (VEGF, FGF), enhancing cardiomyocyte survival (paracrine anti-apoptotic signals), and modulating inflammatory infiltration (reduced macrophage pro-inflammatory activation). One hundred twenty-four registered clinical trials and twelve actively recruiting sites explore intracoronary or intravenous MSC delivery in post-infarction left-ventricular dysfunction, dilated cardiomyopathy, and advanced heart failure awaiting transplantation.
| Indicative cost · Bulgaria (EU) | €3,000–€8,000 |
|---|---|
| Global market cost range | €18,400–€46,000 (dvcstem.com) |
| Main cell types studied | MSCs from Amniotic Membrane, Exosomes |
| Approval status | Investigational |
| Registered trials (ClinicalTrials.gov) | 124 · 12 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Clinical trial data encompasses phase I–II safety documentation and phase II efficacy assessment across >3,000 treated patients globally. Representative studies report left-ventricular ejection fraction (LVEF) improvements of 5–10 percentage points (e.g., 25% → 35%) in 40–55% of treated cohorts over 6–12 months. Cardiac magnetic resonance imaging shows reduction in scar size and infarct zone wall thickness in responders. Exercise tolerance (6-minute walk distance, VO₂ max) improves modestly in 45–50%. Hospitalisation rates for acute decompensation decline by 25–40% in some cohorts over 12-month follow-up. Mortality benefit remains unproven in phase II; pivotal trials are ongoing.
Depending on assessment, a Heart Failure & Cardiac Repair protocol may draw on:
Heart-failure stem-cell protocols in Sofia and international centres range €6,000–9,000 for treatment courses, typically incorporating 1–2 intracoronary or intravenous MSC infusions, baseline and serial cardiac imaging (echocardiography, cardiac MRI, coronary angiography), biomarker panels (BNP, troponin, inflammatory cytokines), and cardiology supervision. Catheterisation-lab facility fees and interventional cardiology expertise add substantially. Repeat treatment cycles incur cumulative costs; some protocols recommend re-dosing at 6–12 month intervals if functional decline recurs.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, or see the Heart Failure & Cardiac Repair cost-by-country breakdown.
Before booking, check safety & regulation, the recovery climate, whether you may be a candidate, and which cell type fits Heart Failure & Cardiac Repair.
Full Heart Failure & Cardiac Repair FAQ → · Heart Failure & Cardiac Repair cost breakdown →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Am I a candidate? · Which cell type? · Types of clinics & best countries · Cost calculator
Medically reviewed by StemCellAtlas’s editorial team with the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка